A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3607-3617

  Ahn, Richard W ^a,b   Chen, Feng ^b   Chen, Haimei ^a,b   Stern, Stephan T ^c   Clogston, Jeffrey D ^c   Patri, Anil K ^c   Raja, Meera R ^a,b   Swindell, Elden P ^a,b   Parimi, Vamsi ^b   Cryns, Vincent L ^b   O'Halloran, Thomas V ^a,b,d  

^a Chemistry of Life Processes Institute ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SAIC FREDERICK INC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; OXIDES; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954735171     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0068     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
3. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
4. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008;14: 8010-8.
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34. (Pubitemid 47219710)
6. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14.
7. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001;6 Suppl 2:22-8.
8. Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol 2008;21:659-66.
9. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006;7:192-8.
10. Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004;28:891-900.
11. Baj G, Arnulfo A, Deaglio S, et al. Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 2002;73:61-73. (Pubitemid 34548166)
12. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
13. Lu J, Chew E-H, Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 2007;104:12288-93. (Pubitemid 47206130)
14. Zhang J, Wang B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 2006;103:199-206. (Pubitemid 44374690)
15. Yu J, Qian H, Li Y, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 2007;106:400-6. (Pubitemid 47096659)
16. Chen Z, Chen GQ, Shen ZX, et al. Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 2002;39:22-6.
17. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev 2007;33:542-64.
18. Maeda H, Hori S, Ohizumi H, et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004;11:737-46. (Pubitemid 39023120)
19. Brunet C, Luyckx M, Cazin M. Pharmacokinetics of arsenic trioxide in the mouse. Toxicol Eur Res 1982;4:175-9.
20. Verstovsek S, Giles F, Quintas-Cardama A, et al. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol 2006;24:181-8.
21. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504.
22. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
23. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007;2:751-60. (Pubitemid 350223348)
24. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1993;1149:180-4.
25. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999;460:129-33. (Pubitemid 29479257)
26. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
27. Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res 2004;14:27-38. (Pubitemid 39310568)
28. Yang Z, Yang M, Peng J. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy. Drug Dev Ind Pharm 2008;34:834-9.
29. Dhubhghaill ON, Sadler P. The structure and reactivity of arsenic compounds: biological activity and drug design. Bioinorg Chem 1991:129-90.
30. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009.
31. Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, O'Halloran TV. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc 2006; 128:13348-9. (Pubitemid 44583006)
32. Chen H, Pazicini S, Krett N, et al. Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl 2009;4:9295-9.
33. Moyano JV, Evans JR, Chen F, et al. αB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116:261-70.
34. Resources IoLA. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
35. Rahman M, Davis S, Pumphrey J, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009;113:217-30.
36. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-7.
37. Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001;61:5432-40.
38. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007;67:7055-8.
39. Kindler HL, Aklilu M, Nattam S, Vokes EE. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol 2008;31:553-6.
40. Bael TE, Peterson BL, Gollob JA. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 2008;18:147-51.
41. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
42. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 2001;1:277-351.